Pharmaceutical company Lupin Ltd on Thursday (November 6) reported a 73.34% year-on-year increase in net profit to ₹1,478 crore for the quarter ended September 2025, compared with ₹852.6 crore in the same period last year. The company’s net profit exceeded the CNBC-TV18 poll estimate of ₹1,217.8 crore.

Revenue from operations grew 24.2% year-on-year to ₹7,047.5 crore, surpassing the CNBC-TV18 poll of ₹6,559.4 crore and compared with ₹5,672.7 crore in Q2 FY25.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 74.7% to ₹2,341.7 crore, against ₹1,340.5 crore a year ago, exceeding the CNBC-TV18 estimate of ₹1,774.2 crore. The company’s EBITDA margin stood at 33.2%, up from 23.6% in the corresponding quarter of the previous year and above the poll estimate of 27%.

See Full Page